Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV-1 infection.~* Documented level of HIV-1 RNA at initiation of antiretroviral treatments~* Prior antiretroviral regimen, including at least 2 NRTIs combined to 1 PI or NNRTI or a third NRTI for at least 18 months prior to study entry.~* CD4 count of 200 cells per mm3 or greater.~* Viral load below 400 copies per ml within 18 months prior to entry and below 50 copies per mL at entry.~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Previous virological failure under prior PI-based regimen.~* Prior therapy in the darunavir.~* HIV-2 infected patients.~* Absence of documented level of HIV-1 RNA at initiation of antiretroviral treatments~* Hepatitis B or C infection within 90 days prior to study entry.~* Therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry.~* Serious acute illness requiring systemic treatment or hospitalization in the 14 days prior to study entry.~* Treatment for an active AIDS defining opportunistic infection within 30 days prior to screening~* Drug or alcohol use or any dependence that would interfere with compliance.~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).